Lumefantrine - NDSRI's
References
FAQ's
References
- Blessborn, D.; Roemsing, S.; Annerberg, A.; Sundquist, D.; Bjoerkman, A.; Lindegardh, N.; Bergqvist, Y., Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper, Journal of Pharmaceutical and Biomedical Analysis, Volume: 45, Issue: 2, Pages: 282-287, 2007 DOI: (1016/j.jpba.2007.07.015)
- Zeng, Mei-Yi; Lu, Zhi-Liang; Yang, Song-Cheng; Zhang, Min; Liao, Jie; Liu, Shu-Ling; Teng, Xi-He, Determination of benflumetol in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection, Journal of Chromatography B: Biomedical Sciences and Applications, Volume: 681, Issue: 2, Pages: 299-306, 1996 DOI: (1016/0378-4347(95)00542-0)
Frequently Asked Questions
Which analytical method identifies and separates Lumefantrine impurities?
The HPLC-DAD method helps to identify and separate Lumefantrine impurities.
How do the Lumefantrine impurities and degradation products form?
Unreacted starting materials, by-products, reagents, and catalysts during synthesis and poor storage conditions may form Lumefantrine impurities and degradation products.
Why should Lumefantrine be removed from the drug?
Lumefantrine impurities' presence in the drug can affect its safety, quality, and efficacy.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.